gene editing

Researchers report that epigenetic editing can silence hepatitis B virus, effectively banishing it rather than merely suppressing it. The approach targets the virus's gene activity without cutting DNA, offering a possible route toward a functional cure for a infection that affects hundreds of millions and is a leading cause of liver cancer. Readers are discussing the promise and hurdles before human use.

A one-time CRISPR gene-editing treatment reportedly cut LDL, or "bad," cholesterol roughly in half, with effects lasting a full year. The finding suggests gene editing could one day offer a durable alternative to daily statins for people at risk of heart disease. Coverage is drawing attention to the potential of permanent, single-dose therapies for one of the world's leading causes of death, though longer and larger trials will be needed before wide use.

Scientists report engineering a miniature CRISPR enzyme that is 60 times more powerful at gene editing than before. The boost in efficiency could make compact gene-editing tools more effective for therapies and research, especially where delivery space is limited. The advance highlights ongoing efforts to shrink and strengthen CRISPR systems for medical use.

Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.